Ensysce Achieves 50% PF614-301 Enrollment, Secures IRB Approval and Expands Patents
Ensysce reached 50% of target enrollment in its pivotal PF614-301 Phase 3 trial and secured IRB approval to initiate Part 3 of the PF614-MPAR-102 overdose-protection study after closing a second financing tranche. It published first peer-reviewed data on MPAR® technology and expanded patent coverage for opioid and ADHD programs.
1. Q1 Clinical Progress
Ensysce achieved 50% enrollment in its PF614-301 Phase 3 trial across two U.S. sites and secured IRB approval to commence Part 3 of the PF614-MPAR-102 overdose-protection study following quarter-end.
2. Strategic Financing and Review
The company closed a second financing tranche under its existing facility and the Board launched a formal review of strategic alternatives, including potential partnerships and licensing opportunities to accelerate its TAAP™ and MPAR® platforms.
3. Pipeline and Patent Expansion
Ensysce published the first peer-reviewed clinical data validating its MPAR® overdose-protection technology and expanded its patent estate across both opioid and ADHD programs, highlighted by a European Notice of Allowance for the PF8026 amphetamine prodrug.